HOUSTON, Aug. 3, 2023 /PRNewswire/ — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that it will report its financial results for the second quarter ended June 30, 2023,…Read More
Moleculin to Report Second Quarter Financial Results on August 11 2023 and Host Conference Call and Webcast
